Last €64.43 EUR
Change Today -0.466 / -0.72%
Volume 402.0
CG3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 7:00 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CG3) Snapshot

Open
€64.67
Previous Close
€64.90
Day High
€64.70
Day Low
€64.38
52 Week High
07/7/14 - €68.45
52 Week Low
04/15/14 - €48.55
Market Cap
51.6B
Average Volume 10 Days
1.8K
EPS TTM
--
Shares Outstanding
800.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP (CG3)

celgene corp (CG3) Related Businessweek News

View More BusinessWeek News

celgene corp (CG3) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company’s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company’s pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders; and strategic alliance with Forma Therapeutics. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

5,100 Employees
Last Reported Date: 02/13/14
Founded in 1980

celgene corp (CG3) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $1.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $753.3K
Chief Operations Officer, Executive Vice Pres...
Total Annual Compensation: $645.8K
Global Head Hematology & Oncology and Executi...
Total Annual Compensation: $666.7K
Compensation as of Fiscal Year 2013.

celgene corp (CG3) Key Developments

Celgene Corporation Announces Unaudited Consolidated Earnings Results for the Three Months and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Full Year of 2014

Celgene Corporation announced unaudited consolidated earnings results for the three months and six months ended June 30, 2014. For the three months, the company reported total revenue was $1,872.7 million compared with $1,599.0 million for the same period in the last year. Operating income was $758.9 million compared with $563.7 million for the same period in the last year. Income before income taxes was $706.8 million compared with $557.8 million for the same period in the last year. Net income was $597.8 million compared with $478.1 million for the same period in the last year. Diluted net incomes per common share were $0.72 compared with $0.56 for the same period in the last year. Adjusted net income was $747.9 million compared with $652.9 million for the same period in the last year. Adjusted diluted earnings per share (EPS) increased 18% to $0.90 from $0.76, on a split-adjusted basis. For the six months, the company reported total revenue was $3,602.7 million compared with $3,063.6 million for the same period in the last year. Operating income was $1,120.7 million compared with $1,027.5 million for the same period in the last year. Income before income tax was $1,039.1 million compared with $1,006.2 for the same period in the last year. Net income was $877.5 million compared with $863 million for the same period in the last year. Diluted net incomes per common share were $1.05 compared with $1.00 for the same period in the last year. Adjusted net income was $1,452.8 million compared with $1,244.6 million for the same period in the last year. For 2014, the company expects, total revenue raised to approximately $7,600 million from $7,500 million, an increase of approximately 17% year-over-year. Total net product sales raised to above $7,500 million from the previous range of $7,300 million to $7,400 million, an increase of approximately 18% over 2013. Adjusted diluted EPS raised to a range of $3.60 to $3.65 from the previous range of $3.50 to $3.60, an increase of approximately 22% over 2013 adjusted diluted EPS. GAAP diluted EPS is expected to be in the range of $2.46 to $2.55 from the previous range of $2.47 to $2.59. The company expects net income to be in the range from $2,058 million to $2,130.1 million and adjusted net income to be in the range from $3,006 million to $3,047.8 million.

Celgene Corporation Announces Results of its Phase III Posture Study Evaluating OTEZLA

Celgene Corporation announced results of its phase III POSTURE study evaluating OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS (Assessment of SpondyloArthritis international Society) 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing. An independent data monitoring committee (DMC) recommended that the study proceed unchanged, based on an assessment of the safety and efficacy data at week 24. According to the protocol, magnetic resonance imaging (MRI) data will be collected in a subgroup of subjects at week 52 and at additional time points, and radiographs will be taken on all study patients at week 104 and at additional time points. The safety and tolerability data observed in the POSTURE study are consistent with previously reported phase II data in ankylosing spondylitis, as well as six phase III studies of OTEZLA in psoriatic arthritis or psoriasis. No new safety signals were observed. The evaluation of safety and efficacy in the treatment arms is ongoing and the results of the study will be presented at an upcoming medical meeting. These results are from an investigational phase III study. OTEZLA is not approved for the treatment of patients with ankylosing spondylitis in any country.

Celgene Corporation to Report Q2, 2014 Results on Jul 24, 2014

Celgene Corporation announced that they will report Q2, 2014 results at 9:00 AM, US Eastern Standard Time on Jul 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €64.43 EUR -0.466

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $335.45 USD -1.34
Bristol-Myers Squibb Co $49.39 USD -0.07
Eli Lilly & Co $63.78 USD -0.59
Regeneron Pharmaceuticals Inc $303.09 USD -1.35
Shire PLC 4,949 GBp -13.00
View Industry Companies
 

Industry Analysis

CG3

Industry Average

Valuation CG3 Industry Range
Price/Earnings 50.5x
Price/Sales 9.9x
Price/Book -- Not Meaningful
Price/Cash Flow 40.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.